Navigation Links
Pharmaceutical Key Trends 2011 - Biosimilar Market Overview

NEW YORK, Oct. 24, 2011 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

Pharmaceutical Key Trends 2011 – Biosimilar Market Overview–-Biosimilar-Market-Overview.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical


In 2009, the combined biosimilars market size for the US and five major European markets was $150m. With more than 30 branded biologics with sales of $51bn set to lose patent exclusivity between 2011 and 2015, Datamonitor forecasts that the global biosimilar market will grow from $243m in 2010 to $3.7bn in 2015.

Features and benefits

* Overview of the biosimilar market, with biosimilar definitions in the US, EU and Japan, plus historical and forecast biosimilar sales out to 2015.

* Insight into the key drivers and resistors to biosimilar uptake in the developed and emerging markets.

* Assesses key factors determining successful biosimilar market access, and examines the major biosimilar players and the strategies they implement.

* Analyses biosimilar uptake in the five main European markets and provides insight into the future opportunities for biosimilar players.


Due to their complexity, cost, and development risks, biosimilar production and commercialization in developed markets is concentrated among only a handful of pharma companies, all of which are established generics players.

Despite the Introduction of approval pathways in the US, EU, and Japan, the growing use of biologics, and the need for more cost-effective treatments, all of which help drive biosimilar uptake, there remain a large number of barriers to uptake.

There are relatively few factors which limit the growth of the biosimilar industry in the developing markets, although the Introduction of biosimilar pathways will restrict market access to many domestic biosimilar players, while low purchasing power and a high proportion of out-of-pocket expenditure, coupled with brand loyalty, limit access.

Your key questions answered

* Evaluate the evolving regulatory environment in the US, EU and Japan, and how this impacts biosimilar market access and uptake.

* Gain insight into the deal types among branded, generic and biosimilars players to either enter or bolster their position in the biosimilars market.

* Identify which branded biologics are facing patent expiry and provide significant opportunities for biosimilar developers.

Executive Summary


Strategic scoping and focus

Key findings

Related reports

Upcoming related reports


[Missing title]

Biosimilar definitions

Biosimilar sales in 2009

Biologic sales exposed to potential biosimilar competition during 2011–15

Forecast biosimilar sales, 2010–15

Profitability of biosimilars versus branded biologics and generics


Drivers and resistors to biosimilar uptake in the developed markets

Drivers of biosimilar uptake in developed markets

Neutral factors impacting biosimilar uptake in developed markets

Resistors to biosimilar uptake in developed markets

Drivers and resistors to biosimilar uptake in Brazil, Russia, India, and China

Drivers of biosimilar uptake in emerging markets

Resistors impacting biosimilar uptake in emerging markets


Key factors in determining the success of biosimilar market access

Biosimilar development timeline

Biosimilar development costs

Pros and cons of developing and manufacturing biosimilars in developing markets

Biosimilar approval pathways

Biosimilar producers face a challenging patent environment

Biosimilar pricing in developed markets

Partnerships help drive growth of the biosimilars industry


Key biosimilar players in the developed and emerging markets

Key biosimilar players in the developed markets

Key players in the emerging markets


Biosimilar launches

US biosimilars market

Biosimilars in the five major EU markets

Japanese biosimilars market

Australian biosimilars market

BRIC biosimilars market


Uptake of biosimilar somatropin, filgrastim and epoetin

Biosimilar somatropin

Biosimilar filgrastim

Biosimilar epoetin


Branded biologic patent expiries present opportunities for the biosimilar industry

Biologic patent expiries in the US

Biologic patent expiries in the five major EU markets

Biologic patent expiries in Japan

Biosimilars in development internationally

Biosimilar MAbs and second-generation biosimilars offer the greatest commercial potential


Publications and online articles


Exchange rates used in this report

To order this report:

: Pharmaceutical Key Trends 2011 – Biosimilar Market Overview

More Market Research Report

Check our Real Time Industry Data

Nicolas Bombourg
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PharmaSecure, an Innovator in Pharmaceutical Serialization, Closes $3.9M Investment by Eric Schmidts Innovation Endeavors, Gray Ghost Ventures, Healthtech Capital and the TEEC Angel Fund
2. S1 Pharmaceuticals Appoints Robert Taylor Segraves, MD, PhD, and Robert Pyke, MD, PhD to Its Scientific Advisory Board
3. Valeant Pharmaceuticals to Announce 2011 Third Quarter Results on November 3, 2011
4. Robbins Umeda LLP Announces an Investigation of KV Pharmaceutical Company
5. Cumberland Pharmaceuticals Ranks as one of the Fastest Growing Companies in North America on Deloittes 2011 Technology Fast 500™
6. Onyx Pharmaceuticals Announces Third Quarter 2011 Financial Results Teleconference and Webcast
7. Jazz Pharmaceuticals Announces Third Quarter 2011 Results Conference Call on November 1
8. Arrien Pharmaceuticals Appoints Dr. Philip LoGrasso to its Scientific Advisory Board for CNS/Neurodegenerative Diseases
9. Critical Alerts For Intel, Mosaic, Deckers, Foot Locker, and Jazz Pharmaceuticals Released By Seven Summits Research
10. Pacira Pharmaceuticals, Inc. Announces New Data Demonstrating Longer Time to First Opioid Use and Reduction in Opioid-Related Adverse Events With EXPAREL™ Compared to Bupivacaine HCl
11. Amylin Pharmaceuticals Reports Third Quarter Financial Results
Post Your Comments:
(Date:10/8/2015)... 8, 2015  Ardelyx, Inc. (NASDAQ: ARDX ... and cardio-renal diseases, today announced that clinical data ... be presented at the 2015 American College of ... measures of sustained response in IBS-C patients enrolled ... Phase 2 trial. The meeting will be held ...
(Date:10/8/2015)... 2015  Allergan plc (NYSE: AGN ), a ... hold its R&D Day on November 4, from 11:00 ... 1:00 p.m. PT). The company will also host its ... a.m. ET (6:00 a.m. PT). ... --> Logo - ...
(Date:10/8/2015)... , Oct. 8, 2015  The National ... approximately $40 million to the Broad Institute of ... sequencing of 20,000 individuals, as well as data ... metabolite profiling. Trans-Omics for Precision Medicine ... step toward a larger initiative, which will use ...
Breaking Medicine Technology:
... MELVILLE, N.Y., April 23, 2012  Henry Schein, ... provider of health care products and services to dental, ... with the launch of its 2012 Global Reflections program ... "Henry Schein firmly believes that protecting ...
... Systems, Inc. (NASDAQ: DCTH ) today announced it ... revolver with Silicon Valley Bank ("SVB"), a leading provider of ... available for general corporate purposes supporting the overall growth and ... transaction, Eamonn P. Hobbs, President & CEO of Delcath Systems, ...
Cached Medicine Technology:
(Date:10/9/2015)... Francisco, CA (PRWEB) , ... October 09, 2015 ... ... Geneva, Switzerland for highly sought after internships at the pre-eminent organization in global ... movement dedicated to eliminating social and health disparities. These internships are a mechanism ...
(Date:10/9/2015)... ... ... "My spouse and I rely on canes to walk, and we both have ... Buffalo, N.Y. "This is not only frustrating but it’s unsanitary. My design solves this ... to keep a cane upright while it’s not in use. It prevents the cane ...
(Date:10/9/2015)... ... ... Head Over Heels Athletic Arts gymnast, Madelyn Williams, will attend the USA ... Huntsville, Texas on October 17-21. , "It's very exciting to be invited to ... director, said. “It's a stepping stone into the U.S. elite system where Maddie and ...
(Date:10/9/2015)... ... October 09, 2015 , ... Confidence Plus Insurance ... a community improvement initiative that involves working with a series of local charities ... of Confidence Plus Insurance is the Gleason Park Electric Violin Ensemble (GPEVE). , ...
(Date:10/9/2015)... ... October 09, 2015 , ... MMJ PhytoTech Limited ... Ed Begley Jr., airing 1st QT 2016 via the Discovery Channel. Dates and ... Phytotech Limited (MMJ) – a global leader in the field of commercializing medicinal ...
Breaking Medicine News(10 mins):
... News) -- Crohn,s disease may cause post-traumatic stress disorder ... nearly 600 Swiss adults with Crohn,s disease, an incurable ... The study participants underwent PTSD assessment at the ... were found to have the disorder. All the participants ...
... News) -- A U.S. Food and Drug Administration advisory committee ... prevention of prostate cancer, the third-highest cancer killer of men. ... the risks of Merck,s Proscar outweighed its benefits, according to ... the panel voted 14-2, with two abstentions, against GlaxoSmithKline,s Avodart. ...
... veterans are nearly three times as likely as civilians ... researchers at Portland State University (PSU) and Oregon Health ... Deaths Among Women With U.S. Military Service: A Hidden ... Psychiatric Services , a journal published by the American ...
... HealthDay Reporter , WEDNESDAY, Dec. 1 (HealthDay News) -- The ... from CT scans may be lower than previously thought, new ... Wednesday at the annual meeting of the Radiological Society of ... of Medicare records covering nearly 11 million patients. , "What ...
... , WEDNESDAY, Dec. 1 (HealthDay News) -- The case of ... colitis -- and actually got better -- sheds light on ... study suggests. "Our findings in this case report suggest ... roundworm can alleviate the symptoms of ulcerative colitis," said ...
... Medicine (BUSM) have identified a mechanism by which specific viruses ... This finding, which is currently featured in an online edition ... to the development of more targeted treatments against many types ... Dunn, a postdoctoral fellow, under the direction of John H. ...
Cached Medicine News:
... Tri-Flo® suction catheter design was created ... patients while still providing high suctioning ... (5/6, 8 or 10 Fr) feature ... catheter placement. Our complete catheter line ...
Tracheal Suction Latex Rubber Catheters - Funnel End...
Rubber bronchial coude catheter, X-ray opaque, one eye, whistle tip....
KCIs KinAir IV combines Advanced Pressure Relief Therapy with a manual wound care turn to provide optimum skin care and patient,positioning....
Medicine Products: